E.NahedG.AzizA.BedourL
Understanding your genetic profile helps your provider anticipate side effects and personalize your treatment plan, including whether a lower starting dose or different compound might reduce cold sensitivity while maintaining weight loss benefits
DA-CH5 reduced amyloid plaques and phosphorylated tau [112], while DA-CH3 reduced amyloid plaque as well as resolving endoplasmic reticulum stress and derailed autophagy [111]
Specifically, the FDA has approved semaglutide for adults who are clinically obese (BMI of 30 or higher) or overweight (BMI of 27 or higher) when accompanied by at least one weight-related health condition, such as hypertension, hyperlipidemia, cardiovascular disease, prediabetes, or obstructive sleep apnea
This week I wanted to spotlight something Ive been hearing more and more about online and in practice, the unexpected impact GLP-1s can have on Aug 19, 2025 See all The GLP-1 Dietitian Hub Go to resource for health professionals working with GLP-1s
Understanding this is essential before you choose